Long non‑coding RNA TMPO‑AS1 promotes cell proliferation, migration, invasion and epithelial‑to‑mesenchymal transition in gallbladder carcinoma by regulating the microRNA‑1179/E2F2 axis

Sui,Zhenghui; Sui,Xin

doi:10.3892/ol.2021.13116

Long non‑coding RNA TMPO‑AS1 promotes cell proliferation, migration, invasion and epithelial‑to‑mesenchymal transition in gallbladder carcinoma by regulating the microRNA‑1179/E2F2 axis

Authors:
- Zhenghui Sui
- Xin Sui
View Affiliations

Affiliations: Department of General Surgery, The People's Hospital of Danyang and Affiliated Danyang Hospital of Nantong University, Danyang, Jiangsu 212300, P.R. China
Published online on: October 29, 2021 https://doi.org/10.3892/ol.2021.13116
Article Number: 855
Copyright: © Sui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gallbladder carcinoma (GBC), which is a common tumor of the biliary system, poses a serious threat to human life and health. The present study aimed to investigate the molecular mechanism of the long non‑coding (lnc)RNA thymopoietin antisense transcript 1 (TMPO‑AS1)/microRNA (miRNA/miR)‑1179/E2F transcription factor 2 (E2F2) axis in GBC. The viability, proliferation, migration, invasion and epithelial‑to‑mesenchymal transition (EMT) of GBC cell lines were assessed via the Cell Counting Kit‑8, colony formation, Transwell migration and invasion, immunofluorescence and western blot assays. In the present study, lncRNA TMPO‑AS1 was significantly upregulated in clinical GBC tissues and cell lines, and was highly expressed in stage III+IV patients with GBC compared with stage I+II patients with GBC. In addition, the overall survival rate of patients with low TMPO‑AS1 expression levels was higher than those with high TMPO‑AS1 expression levels. Furthermore, TMPO‑AS1 knockdown inhibited the viability, proliferation, migration, invasion and EMT of GBC cell lines. In addition, miR‑1179 expression was downregulated in clinical GBC tissues and cell lines, and negatively correlated with TMPO‑AS1 expression. The results revealed that miR‑1179 is a target of TMPO‑AS1, which was confirmed via the dual‑luciferase reporter assay and RNA pull‑down analysis. Overexpression of miR‑1179 inhibited the viability, proliferation, migration, invasion and EMT of GBC cell lines. Furthermore, E2F2 was verified as a direct target of miR‑1179 by binding to its 3'‑untranslated region. E2F2 expression was significantly upregulated in clinical GBC tissues and cell lines, and negatively correlated with miR‑1179 expression. Notably, E2F2 knockdown partially hindered the effects of TMPO‑AS1/miR‑1179 on the proliferation and metastasis of GBC cell lines. Taken together, the results of the present study suggest that TMPO‑AS1 potentially plays a tumor‑promoting role in the occurrence and development of GBC, which may be achieved by regulating the miR‑1179/E2F2 axis.

View Figures

View References

1	Sharma A, Sharma KL, Gupta A, Yadav A and Kumar A: Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update. World J Gastroenterol. 23:3978–3998. 2017. View Article : Google Scholar : PubMed/NCBI
2	Baiu I and Visser B: Gallbladder Cancer. JAMA. 320:12942018. View Article : Google Scholar : PubMed/NCBI
3	Hickman L and Contreras C: Gallbladder Cancer: Diagnosis, Surgical Management, and Adjuvant Therapies. Surg Clin North Am. 99:337–355. 2019. View Article : Google Scholar : PubMed/NCBI
4	Yifan T, Zheyong L, Miaoqin C, Liang S and Xiujun C: A predictive model for survival of gallbladder adenocarcinoma. Surg Oncol. 27:365–372. 2018. View Article : Google Scholar : PubMed/NCBI
5	Vega EA, Sanhueza M and Viñuela E: Minimally Invasive Surgery for Gallbladder Cancer. Surg Oncol Clin N Am. 28:243–253. 2019. View Article : Google Scholar : PubMed/NCBI
6	Bhan A, Soleimani M and Mandal SS: Long Noncoding RNA and Cancer: A New Paradigm. Cancer Res. 77:3965–3981. 2017. View Article : Google Scholar : PubMed/NCBI
7	Zhang Y and Tang L: The Application of lncRNAs in Cancer Treatment and Diagnosis. Recent Patents Anticancer Drug Discov. 13:292–301. 2018. View Article : Google Scholar : PubMed/NCBI
8	Castro-Oropeza R, Melendez-Zajgla J, Maldonado V and Vazquez-Santillan K: The emerging role of lncRNAs in the regulation of cancer stem cells. Cell Oncol (Dordr). 41:585–603. 2018. View Article : Google Scholar : PubMed/NCBI
9	Wang J, Liu H, Shen X, Wang Y, Zhang D, Shen S, Suo T, Pan H, Ming Y, Ding K, et al: Long non-coding RNA expression profiles in gallbladder carcinoma identified using microarray analysis. Oncol Lett. 13:3508–3516. 2017. View Article : Google Scholar : PubMed/NCBI
10	Hu YP, Jin YP, Wu XS, Yang Y, Li YS, Li HF, Xiang SS, Song XL, Jiang L, Zhang YJ, et al: LncRNA-HGBC stabilized by HuR promotes gallbladder cancer progression by regulating miR-502-3p/SET/AKT axis. Mol Cancer. 18:1672019. View Article : Google Scholar : PubMed/NCBI
11	Ji D, Zhong X, Jiang X, Leng K, Xu Y, Li Z, Huang L, Li J and Cui Y: The role of long non-coding RNA AFAP1-AS1 in human malignant tumors. Pathol Res Pract. 214:1524–1531. 2018. View Article : Google Scholar : PubMed/NCBI
12	Chen J, Yu Y, Li H, Hu Q, Chen X, He Y, Xue C, Ren F, Ren Z, Li J, et al: Long non-coding RNA PVT1 promotes tumor progression by regulating the miR-143/HK2 axis in gallbladder cancer. Mol Cancer. 18:332019. View Article : Google Scholar : PubMed/NCBI
13	Liang C, Yang P, Han T, Wang RY, Xing XL, Si AF, Ma QY, Chen Z, Li HY and Zhang B: Long non-coding RNA DILC promotes the progression of gallbladder carcinoma. Gene. 694:102–110. 2019. View Article : Google Scholar : PubMed/NCBI
14	Yang L, Cheng X, Ge N, Guo W, Feng F and Wan F: Long non-coding RNA SPRY4-IT1 promotes gallbladder carcinoma progression. Oncotarget. 8:3104–3110. 2017. View Article : Google Scholar : PubMed/NCBI
15	Huang W, Su X, Yan W, Kong Z, Wang D, Huang Y, Zhai Q, Zhang X, Wu H, Li Y, et al: Overexpression of AR-regulated lncRNA TMPO-AS1 correlates with tumor progression and poor prognosis in prostate cancer. Prostate. 78:1248–1261. 2018. View Article : Google Scholar : PubMed/NCBI
16	Guo X and Wang Y: LncRNA TMPO-AS1 promotes hepatocellular carcinoma cell proliferation, migration and invasion through sponging miR-329-3p to stimulate FOXK1-mediated AKT/mTOR signaling pathway. Cancer Med. 9:5235–5246. 2020. View Article : Google Scholar : PubMed/NCBI
17	Gang X, Yuan M and Zhang J: Long Non-Coding RNA TMPO-AS1 Promotes Cervical Cancer Cell Proliferation, Migration, and Invasion by Regulating miR-143-3p/ZEB1 Axis. Cancer Manag Res. 12:1587–1599. 2020. View Article : Google Scholar : PubMed/NCBI
18	Luo H, Yang L, Liu C, Wang X, Dong Q, Liu L and Wei Q: TMPO-AS1/miR-98-5p/EBF1 feedback loop contributes to the progression of bladder cancer. Int J Biochem Cell Biol. 122:1057022020. View Article : Google Scholar : PubMed/NCBI
19	Edge SB and Compton CC: The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
20	Hua CB, Song SB, Ma HL and Li XZ: MiR-1-5p is down-regulated in gallbladder carcinoma and suppresses cell proliferation, migration and invasion by targeting Notch2. Pathol Res Pract. 215:200–208. 2019. View Article : Google Scholar : PubMed/NCBI
21	Nepal C, Zhu B, O'Rourke CJ, Bhatt DK, Lee D, Song L, Wang D, Van Dyke AL, Choo-Wosoba H, Liu Z, et al: Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes. J Hepatol. 74:1132–1144. 2021. View Article : Google Scholar : PubMed/NCBI
22	Khan MR and Begum S: Extended resection for xanthogranulomatous cholecystitis mimicking gallbladder carcinoma: Cases and review of diagnostic approach. J Pak Med Assoc. 69:256–260. 2019.PubMed/NCBI
23	Yadav S, DE Sarkar N, Kumari N, Krishnani N, Kumar A and Mittal B: Targeted Gene Sequencing of Gallbladder Carcinoma Identifies High-impact Somatic and Rare Germline Mutations. Cancer Genomics Proteomics. 14:495–506. 2017.PubMed/NCBI
24	Wang SH, Zhang WJ, Wu XC, Weng MZ, Zhang MD, Cai Q, Zhou D, Wang JD and Quan ZW: The lncRNA MALAT1 functions as a competing endogenous RNA to regulate MCL-1 expression by sponging miR-363-3p in gallbladder cancer. J Cell Mol Med. 20:2299–2308. 2016. View Article : Google Scholar : PubMed/NCBI
25	Peng WX, Koirala P and Mo YY: LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 36:5661–5667. 2017. View Article : Google Scholar : PubMed/NCBI
26	Mitobe Y, Ikeda K, Suzuki T, Takagi K, Kawabata H, Horie-Inoue K and Inoue S: ESR1-Stabilizing Long Noncoding RNA TMPO-AS1 Promotes Hormone-Refractory Breast Cancer Progression. Mol Cell Biol. 39:e00261–e00269. 2019. View Article : Google Scholar : PubMed/NCBI
27	Yang J, Liang B and Hou S: TMPO-AS1 promotes cervical cancer progression by upregulating RAB14 via sponging miR-577. J Gene Med. 21:e31252019. View Article : Google Scholar : PubMed/NCBI
28	Qin Z, Zheng X and Fang Y: Long noncoding RNA TMPO-AS1 promotes progression of non-small cell lung cancer through regulating its natural antisense transcript TMPO. Biochem Biophys Res Commun. 516:486–493. 2019. View Article : Google Scholar : PubMed/NCBI
29	Mu X, Wu H, Liu J, Hu X, Wu H, Chen L, Liu W, Luo S and Zhao Y: Long noncoding RNA TMPO-AS1 promotes lung adenocarcinoma progression and is negatively regulated by miR-383-5p. Biomed Pharmacother. 125:1099892020. View Article : Google Scholar : PubMed/NCBI
30	Cui H and Zhao J: LncRNA TMPO-AS1 serves as a ceRNA to promote osteosarcoma tumorigenesis by regulating miR-199a-5p/WNT7B axis. J Cell Biochem. 121:2284–2293. 2020. View Article : Google Scholar : PubMed/NCBI
31	Peng X, Yan J and Cheng F: LncRNA TMPO-AS1 up-regulates the expression of HIF-1α and promotes the malignant phenotypes of retinoblastoma cells via sponging miR-199a-5p. Pathol Res Pract. 216:1528532020. View Article : Google Scholar : PubMed/NCBI
32	Mitobe Y, Ikeda K, Sato W, Kodama Y, Naito M, Gotoh N, Miyata K, Kataoka K, Sasaki H, Horie-Inoue K, et al: Proliferation-associated long noncoding RNA, TMPO-AS1, is a potential therapeutic target for triple-negative breast cancer. Cancer Sci. 111:2440–2450. 2020. View Article : Google Scholar : PubMed/NCBI
33	Li Y and Qin C: MiR-1179 inhibits the proliferation of gastric cancer cells by targeting HMGB1. Hum Cell. 32:352–359. 2019. View Article : Google Scholar : PubMed/NCBI
34	Li WJ, Xie XX, Bai J, Wang C, Zhao L and Jiang DQ: Increased expression of miR-1179 inhibits breast cancer cell metastasis by modulating Notch signaling pathway and correlates with favorable prognosis. Eur Rev Med Pharmacol Sci. 22:8374–8382. 2018.PubMed/NCBI
35	Lin C, Hu Z, Yuan G, Su H, Zeng Y, Guo Z, Zhong F, Jiang K and He S: MicroRNA-1179 inhibits the proliferation, migration and invasion of human pancreatic cancer cells by targeting E2F5. Chem Biol Interact. 291:65–71. 2018. View Article : Google Scholar : PubMed/NCBI
36	Zhang ZH, Chen RB, Lu LP, Mao AP, Guo H, Wu YT and Shan ZX: MicroRNA-1179 regulates proliferation and chemosensitivity of human ovarian cancer cells by targeting the PTEN-mediated PI3K/AKT signaling pathway. Arch Med Sci. 16:907–914. 2019. View Article : Google Scholar
37	Wang S, Wang L, Wu C, Sun S and Pan JH: E2F2 directly regulates the STAT1 and PI3K/AKT/NF-κB pathways to exacerbate the inflammatory phenotype in rheumatoid arthritis synovial fibroblasts and mouse embryonic fibroblasts. Arthritis Res Ther. 20:2252018. View Article : Google Scholar : PubMed/NCBI
38	Clijsters L, Hoencamp C, Calis JJA, Marzio A, Handgraaf SM, Cuitino MC, Rosenberg BR, Leone G and Pagano M: Cyclin F Controls Cell-Cycle Transcriptional Outputs by Directing the Degradation of the Three Activator E2Fs. Mol Cell. 74:1264–1277.e7. 2019. View Article : Google Scholar : PubMed/NCBI
39	Iglesias-Ara A, Zenarruzabeitia O, Buelta L, Merino J and Zubiaga AM: E2F1 and E2F2 prevent replicative stress and subsequent p53-dependent organ involution. Cell Death Differ. 22:1577–1589. 2015. View Article : Google Scholar : PubMed/NCBI
40	Zhou Q, Zhang F, He Z and Zuo MZ: E2F2/5/8 Serve as Potential Prognostic Biomarkers and Targets for Human Ovarian Cancer. Front Oncol. 9:1612019. View Article : Google Scholar : PubMed/NCBI
41	Yao H, Lu F and Shao Y: The E2F family as potential biomarkers and therapeutic targets in colon cancer. Peer J. 8:e85622020. View Article : Google Scholar : PubMed/NCBI
42	Zhang Y, Han D, Wei W, Cao W, Zhang R, Dong Q, Zhang J, Wang Y and Liu N: MiR-218 Inhibited Growth and Metabolism of Human Glioblastoma Cells by Directly Targeting E2F2. Cell Mol Neurobiol. 35:1165–1173. 2015. View Article : Google Scholar : PubMed/NCBI
43	Li X, Zhang Z, Jiang H, Li Q, Wang R, Pan H, Niu Y, Liu F, Gu H, Fan X, et al: Circular RNA circPVT1 Promotes Proliferation and Invasion Through Sponging miR-125b and Activating E2F2 Signaling in Non-Small Cell Lung Cancer. Cell Physiol Biochem. 51:2324–2340. 2018. View Article : Google Scholar : PubMed/NCBI
44	Yao Z, Chen Q, Ni Z, Zhou L, Wang Y, Yang Y and Huang H: Long Non-Coding RNA Differentiation Antagonizing Nonprotein Coding RNA (DANCR) Promotes Proliferation and Invasion of Pancreatic Cancer by Sponging miR-214-5p to Regulate E2F2 Expression. Med Sci Monit. 25:4544–4552. 2019. View Article : Google Scholar : PubMed/NCBI
45	Huang JW, Luo XY, Li ZH and Lang BP: LncRNA NNT-AS1 regulates the progression of lung cancer through the NNT-AS1/miR-3666/E2F2 axis. Eur Rev Med Pharmacol Sci. 24:238–248. 2020.PubMed/NCBI